Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension
- 9 September 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Cell Metabolism
- Vol. 118 (11), 1195-1201
- https://doi.org/10.1161/circulationaha.106.674002
Abstract
The availability of new treatments for patients with pulmonary arterial hypertension has increased awareness and interest in the medical community for pulmonary vascular diseases in general. Many uncertainties exist, however, regarding the diagnosis and treatment of patients with pulmonary arterial hypertension that are particularly pertinent for the management of patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with underlying diseases. This review highlights controversial issues around the definition and diagnosis of pulmonary hypertension, the interpretation of hemodynamic variables, and the interpretation of clinical responsiveness to chronic therapies. In addition, we propose guidelines applicable to the conduct of new therapeutic trials in pulmonary arterial hypertension, which aim to provide greater confidence in the efficacy and safety of new treatments currently under development.Keywords
This publication has 51 references indexed in Scilit:
- Chronic Thromboembolic Pulmonary HypertensionCell Metabolism, 2006
- Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.Published by Oxford University Press (OUP) ,2004
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Screening, Early Detection, and Diagnosis of Pulmonary Arterial HypertensionChest, 2004
- IntroductionChest, 2004
- Clinical classification of pulmonary hypertensionJournal of the American College of Cardiology, 2004
- Analysis of Observer Variability in Measurement of Pulmonary Artery Occlusion PressuresAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)American Heart Journal, 1999
- Interobserver Variability in the Interpretation of Pulmonary Artery Catheter Pressure TracingsChest, 1991
- Primary Pulmonary HypertensionAnnals of Internal Medicine, 1987